Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis

CONCLUSION: 4yPSARR is an encouraging early predictor of outcome in patients with intermediate-risk PCa treated with SBRT. Validation in prospective trials is warranted.PMID:34836735 | DOI:10.1016/j.clon.2021.11.004

Source: Clinical Prostate Cancer - November 27, 2021 Category: Cancer & Oncology Authors: R M Glicksman A U Kishan A J Katz C A Mantz S P Collins D B Fuller M L Steinberg D Shabsovich L Zhang A Loblaw Source Type: research